{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:34:19Z","timestamp":1787009659565,"version":"build-2736575974"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union\u2019s Horizon 2020","award":["714312"],"award-info":[{"award-number":["714312"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>ACPA-positive and ACPA-negative RA differ in underlying risk factors but have a similar clinical presentation at RA diagnosis. It is unknown what the ACPA-associated differences or similarities are during the symptomatic at-risk stage of RA, i.e. clinically suspect arthralgia (CSA). To deepen insights into these differences\/similarities, we compared the course of symptoms\/impairments and subclinical joint inflammation in the CSA phase during progression to inflammatory arthritis (IA) or to CSA resolution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 845 CSA patients were followed for a median of 24\u2009months; 136 patients developed IA and an additional 355\/505 patients had resolution of CSA according to rheumatologists. Patient burden (pain, morning stiffness, fatigue, functional disabilities, presenteeism) was assessed at baseline and 4, 12 and 24\u2009months and at IA development. Subclinical joint inflammation in the hands and feet was assessed over time with 1.5T MRI. Linear and Poisson mixed models were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In both ACPA-positive and ACPA-negative patients, patient burden increased towards IA development and decreased towards CSA resolution. However, patient burden was lower in ACPA-positive vs ACPA-negative disease at all timepoints. Conversely, subclinical joint inflammation tended to increase more rapidly during development of ACPA-positive IA [incidence rate ratio (IRR) 1.52 (95% CI 0.94, 2.47), P\u2009=\u20090.089] and remained higher over time in ACPA-positive CSA patients achieving resolution compared with ACPA-negative patients [IRR 1.52 (95% CI 1.07, 2.15), P\u2009=\u20090.018]. Although correlation coefficients between changes in patient burden and subclinical joint inflammation during progression to IA were weak, they were consistently higher in ACPA-positive than ACPA-negative disease, e.g. \u03c1\u2009=\u20090.29 vs 0.12 for functional disabilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>During RA development and CSA resolution, ACPA-positive CSA patients have lower patient burden but more subclinical joint inflammation than ACPA-negative CSA patients. These data strengthen the notion that the development of ACPA-positive and ACPA-negative RA is pathophysiologically different and encourage further research on these differences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae044","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T07:25:44Z","timestamp":1705562744000},"page":"2336-2344","source":"Crossref","is-referenced-by-count":14,"title":["Patient burden and joint inflammation during development of RA from arthralgia: is it similar in ACPA-positive and ACPA-negative disease?"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5953-6844","authenticated-orcid":false,"given":"Sarah J H","family":"Khidir","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Centre , Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1654-1031","authenticated-orcid":false,"given":"Doortje I","family":"Krijbolder","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Centre , Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0140-5934","authenticated-orcid":false,"given":"Herman K","family":"Glas","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Reumazorg ZWN , Goes, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1900-790X","authenticated-orcid":false,"given":"Elise","family":"van Mulligen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Centre , Leiden, The Netherlands"},{"name":"Department of Rheumatology, Erasmus Medical Centre , Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8572-1437","authenticated-orcid":false,"given":"Annette H M","family":"van der Helm-van Mil","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Centre , Leiden, The Netherlands"},{"name":"Department of Rheumatology, Erasmus Medical Centre , Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"2024090404221199300_keae044-B1","doi-asserted-by":"crossref","first-page":"104233","DOI":"10.1016\/j.ebiom.2022.104233","article-title":"ACPA-negative rheumatoid arthritis: from immune mechanisms to clinical translation","volume":"83","author":"Li","year":"2022","journal-title":"EBioMedicine"},{"key":"2024090404221199300_keae044-B2","doi-asserted-by":"crossref","first-page":"e1003296","DOI":"10.1371\/journal.pmed.1003296","article-title":"Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: a longitudinal cohort study in the Netherlands","volume":"17","author":"Matthijssen","year":"2020","journal-title":"PLoS Med"},{"key":"2024090404221199300_keae044-B3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/ard.2009.126821","article-title":"A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis","volume":"70","author":"Padyukov","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024090404221199300_keae044-B4","doi-asserted-by":"crossref","first-page":"R133","DOI":"10.1186\/ar2022","article-title":"Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides","volume":"8","author":"Pedersen","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2024090404221199300_keae044-B5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keac294","article-title":"ACPA-negative and ACPA-positive RA patients achieving disease resolution demonstrate distinct patterns of MRI-detected joint-inflammation","volume":"62","author":"Verstappen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2024090404221199300_keae044-B6","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1136\/annrheumdis-2019-215843","article-title":"Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA","volume":"79","author":"Matthijssen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024090404221199300_keae044-B7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrrheum.2011.204","article-title":"The influence of ACPA status and characteristics on the course of RA","volume":"8","author":"Willemze","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"2024090404221199300_keae044-B8","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/annrheumdis-2016-209794","article-title":"Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present","volume":"76","author":"Derksen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024090404221199300_keae044-B9","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.3899\/jrheum.130884","article-title":"Association of anticyclic citrullinated peptide antibodies and\/or rheumatoid factor status and clinical presentation in early arthritis: results from the ESPOIR cohort","volume":"41","author":"Mouterde","year":"2014","journal-title":"J Rheumatol"},{"key":"2024090404221199300_keae044-B10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fmed.2018.00339","article-title":"The Clinical Value of Autoantibodies in Rheumatoid Arthritis","volume":"5","author":"Bugatti","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"2024090404221199300_keae044-B11","doi-asserted-by":"crossref","first-page":"R949","DOI":"10.1186\/ar1767","article-title":"Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis","volume":"7","author":"van der Helm-van Mil","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"2024090404221199300_keae044-B12","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1136\/annrheumdis-2017-211325","article-title":"Differences in the symptomatic phase preceding ACPA-positive and ACPA-negative RA: a longitudinal study in arthralgia during progression to clinical arthritis","volume":"76","author":"Burgers","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024090404221199300_keae044-B13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(22)01193-X","article-title":"Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial","volume":"400","author":"Krijbolder","year":"2022","journal-title":"Lancet"},{"key":"2024090404221199300_keae044-B14","author":"Het Nederlands Huisartsen Genootschap","year":"2017"},{"key":"2024090404221199300_keae044-B15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-7525-1-20","article-title":"The Stanford Health Assessment Questionnaire: dimensions and practical applications","volume":"1","author":"Bruce","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"2024090404221199300_keae044-B16","doi-asserted-by":"crossref","first-page":"R177","DOI":"10.1186\/ar3141","article-title":"Validity of the work productivity and activity impairment questionnaire\u2014general health version in patients with rheumatoid arthritis","volume":"12","author":"Zhang","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2024090404221199300_keae044-B17","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1093\/rheumatology\/keab793","article-title":"Work participation is reduced during the development of RA, months before clinical arthritis manifests","volume":"61","author":"Rogier","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2024090404221199300_keae044-B18","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1093\/rheumatology\/kew335","article-title":"Older age is associated with more MRI-detected inflammation in hand and foot joints","volume":"55","author":"Nieuwenhuis","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2024090404221199300_keae044-B19","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/acr.23497","article-title":"Is anti-citrullinated protein antibody-positive rheumatoid arthritis still a more severe disease than anti-citrullinated protein antibody-negative rheumatoid arthritis? A longitudinal cohort study in rheumatoid arthritis patients diagnosed from 2000 onward","volume":"70","author":"Boer","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024090404221199300_keae044-B20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/annrheumdis-2015-208873","article-title":"Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-na\u00efve patients classified according to the 2010 ACR\/EULAR criteria","volume":"76","author":"Nordberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024090404221199300_keae044-B21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3899\/jrheum.080479","article-title":"The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials","volume":"36","author":"Pope","year":"2009","journal-title":"J Rheumatol"},{"key":"2024090404221199300_keae044-B22","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3899\/jrheum.110392","article-title":"It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10","volume":"38","author":"Strand","year":"2011","journal-title":"J Rheumatol"},{"key":"2024090404221199300_keae044-B23","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/annrheumdis-2022-222436","article-title":"Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis","volume":"81","author":"Bugatti","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024090404221199300_keae044-B24","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/rheumatology\/keq282","article-title":"Fatigue in rheumatoid arthritis: time for a conceptual model","volume":"50","author":"Hewlett","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2024090404221199300_keae044-B25","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/rheumatology\/keg369","article-title":"A biopsychosocial model of pain and depression in rheumatoid arthritis: a 12-month longitudinal study","volume":"42","author":"Covic","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"2024090404221199300_keae044-B26","doi-asserted-by":"crossref","first-page":"1759720x211022533","DOI":"10.1177\/1759720X211022533","article-title":"Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis","volume":"13","author":"Studenic","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024090404221199300_keae044-B27","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2013-204154","article-title":"Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis","volume":"73","author":"Shi","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024090404221199300_keae044-B28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/annrheumdis-2020-218221","article-title":"Do autoantibody-responses mature between presentation with arthralgia suspicious for progression to rheumatoid arthritis and development of clinically apparent inflammatory arthritis? A longitudinal serological study","volume":"80","author":"Wouters","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024090404221199300_keae044-B29","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/annrheumdis-2014-206598","article-title":"Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis","volume":"75","author":"Rombouts","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae044\/56642139\/keae044.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2336\/59007333\/keae044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2336\/59007333\/keae044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T07:23:14Z","timestamp":1725434594000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/9\/2336\/7585526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,1,23]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae044","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,1,23]]}}}